Three Vietnamese researchers in Hong Kong have solved a 20-year puzzle in molecular biology that could reshape how scientists ...

Dublin, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The "RNA Interference Therapy-Competitive Landscape, 2026" has been added to ResearchAndMarkets.com's offering. The "RNA Interference Therapy - Competitive ...

Discover six RNAi biotech companies helping to drive momentum in a field that can precisely target disease at its genetic root.

(MENAFN- GlobeNewsWire - Nasdaq) RNA interference (RNAi) therapy offers groundbreaking potential to revolutionize disease treatment by targeting gene silencing. Opportunities lie in developing ...

"2025 proved that our technology delivers, not in the distant future, but right now," says Tropic CEO Gilad Gershon.

Benitec Executive Chairman and Chief Executive Officer, Jerel A. Banks, M.D., Ph.D., will share an updated presentation detailing the significant, durable, improvements in dysphagic symptom burden and ...

UK agbiotech Tropic raises $105m to scale gene-edited non-browning and extended shelf-life bananas, and advance TR4-resistant varieties.

Detailed price information for Benitec Biopharma Ltd ADR (BNTC-Q) from The Globe and Mail including charting and trades.

A cell-free genomics approach silences cellular noise and reveals transcription drivers, improving our understanding of a ...

Alpha-1 Antitrypsin Deficiency (AATD) is a rare genetic disorder caused by SERPINA1 gene mutations, leading to conditions like pulmonary emphysema and liver dysfunction. The AATD market is in its ...

Interim clinical study results for the BB-301 Phase 1b/2a Treatment Study including 12-month follow-up results for the first four Cohort 1 ...